Cadila Healthcare has merged with promoter company Zydus Hospitals and Medical Research, as a result of which the Zydus family trust has received 10.08 crore shares, or 73.91 percent stake, of Cadila Healthcare. The trust now holds 74.56 per cent in Cadila. As a result of the merger, the equity share capital has also increased from Rs 62.8 crore to Rs 68.25 crore. In the December quarter, total consolidated income grew nearly 26 per cent to Rs
2,214 crore, whereas EBIDTA grew 32 per cent to Rs 456 crore. There has been an expansion in EBIDTA by nearly 90 basis points on a y-o-y basis. The company expects international sales to more than double from $217 million
in 2007-08 to $450 million by 201 0-1 1,which would imply a 26 per cent topline growth. In this respect, Cadilla plans to increase emphasis on the sale of formulations in regulated and emerging markets and to cut dependence on API! bulk drugs.
Related posts: